Opendata, web and dolomites


40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Total Cost €


EC-Contrib. €






 BRIGHT project word cloud

Explore the words cloud of the BRIGHT project. It provides you a very rough idea of what is the project "BRIGHT" about.

pandemic    human    improvements    disease    savings    believe    formed    representing    prevalence    100bn    hz    maturation    shows    ad    delay    market    optoceutics    triggers    reduce    decades    blue    clinical    ahead    certification    risk    33    protected    accentuates    led    alone    core    untap    setup    business    productization    accumulation    industrial    stroboscopic    cortex    leverage    devised    beta    light    patients    strategy    colour    stages    full    optimal    avoiding    prepare    receptors    demonstration    drugs    variants    invasive    stimulate    colours    coloured    onset    intervention    founding    flashing    white    instead    patent    combinations    vital    capturing    roll    roadblocks    protective    sizeable    liaise    company    damage    appropriate    appear    primarily    amyloid    serving    fadigue    stepping    clearance    approximately    flickering    neuro    while    leds    visual    inducing    wavelengths    bright    alternating    neurodegenerative    promotes    prior    route    minimizing    stone    players    fusion    later    global    brain    irreversible    significantly    members    cascade    dementia    off    alzheimer    ing    experiencing    frequency    de   

Project "BRIGHT" data sheet

The following table provides information about the project.


Organization address
address: DIPLOMVEJ 381
postcode: 2800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTOCEUTICS APS DK (KONGENS LYNGBY) coordinator 50˙000.00


 Project objective

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients. This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia stages, which accentuates the need for early intervention. However, recent evidence shows that non-invasive flashing (stroboscopic) light at the appropriate frequency (40 Hz) promotes clearance of beta-amyloid – whose accumulation is believe to be one of the key triggers to the neurodegenerative cascade leading to dementia states.

Instead of using fadigue-inducing stroboscopic flashing light (i.e. on-off), the founding members of OptoCeutics have devised a unique, patent-protected method to stimulate the human visual receptors and processing cortex through alternating white light composed of different wavelengths. The two variants of the white light are formed by different combinations of coloured LEDs. When flickering between the two LED sets, the colours fusion together and appear as one, resulting in approximately the same white colour, avoiding experiencing light flashing, but the brain is capturing the blue component flashing with 40 Hz – thus still promoting neuro-protective beta-amyloid clearance.

OptoCeutics will leverage from BRIGHT as a vital stepping stone to prepare the company’s business strategy, serving also to significantly de-risk its route-to-market by enabling to liaise with major industrial and clinical players to define both the optimal productization and maturation of Optoceutics core technology, as well as the setup for its full-scale demonstration and certification, prior market roll-out.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

HUD (2018)


Read More